BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/27/2024 11:58:45 AM | Browse: 62 | Download: 147
 |
Received |
|
2023-12-03 16:29 |
|
Peer-Review Started |
|
2023-12-03 16:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-15 12:32 |
|
Revised |
|
2024-01-04 21:52 |
|
Second Decision |
|
2024-01-23 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2024-01-23 07:23 |
|
Articles in Press |
|
2024-01-23 07:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-02-19 07:00 |
|
Publish the Manuscript Online |
|
2024-02-27 11:58 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Advancements in autoimmune hepatitis management: Perspectives for future guidelines
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Marcos Mucenic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marcos Mucenic, MD, PhD, Doctor, Medical Assistant, Liver Transplantation Group, Santa Casa de Porto Alegre, Independencia 75, Porto Alegre 90035-070, RS, Brazil. mmucenic@gmail.com |
| Key Words |
Autoimmune Hepatitis; Treatment; Immunosuppression; Relapse; Remission induction |
| Core Tip |
Autoimmune hepatitis guidelines consider corticosteroids as first-line treatment, including budesonide as an option in patients without cirrhosis. Azathioprine is recommended to reduce corticosteroid doses and side effects. Nevertheless, there are concerns regarding its long-term malignancy risks. Recent publications suggest that these guidelines may be outdated. The efficacy of budesonide can be limited to patients with lower aminotransferases levels. The potential superiority of mycophenolate mofetil to azathioprine is under scrutiny. Additionally, there are controversies regarding treatment suspension, with a potential role for chloroquine for long-term maintenance treatment. Other therapeutic agents are still in the initial stages of research. |
| Publish Date |
2024-02-27 11:58 |
| Citation |
Mucenic M. Advancements in autoimmune hepatitis management: Perspectives for future guidelines. World J Hepatol 2024; 16(2): 135-139 |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i2/135.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i2.135 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
